Home > Insider Trading > Filing (0001883850-23-000062)

Filing Details

Accession Number:: 0001883850-23-000062
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-27 16:41:56
Reporting Period:: 2023-03-23

Accepted Time:: 2023-03-27 16:41:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc.	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1226690	George Yancopoulos	777 Old Saw Mill River Road Tarrytown NY 10591	President And Chief Scientific	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-03-23	254	$800.59	200,250	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	122	$801.16	200,128	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	1,237	$802.54	198,891	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	642	$803.30	198,249	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	254	$804.38	197,995	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	47	$805.55	197,948	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	700	$806.47	197,248	No	4	S	Indirect	By Trust for Chldn.
Common Stock	Disposition	2023-03-23	400	$810.30	196,848	No	4	S	Indirect	By Trust for Chldn.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.
No	4	S	Indirect	By Trust for Chldn.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	569,653	Direct
Common Stock	5,869	Indirect	By 401(k) Plan
Common Stock	200,000	Indirect	by 2022 GRAT I
Common Stock	250,000	Indirect	by 2022 GRAT II

Footnotes

Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022.
Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $800.52 to $800.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
As investment trustee of trusts for the benefit of the reporting person's children.
Represents volume-weighted average price of sales of 122 shares of Company stock on March 23, 2023 at prices ranging from $801.00 to $801.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
Represents volume-weighted average price of sales of 1,237 shares of Company stock on March 23, 2023 at prices ranging from $802.00 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
Represents volume-weighted average price of sales of 642 shares of Company stock on March 23, 2023 at prices ranging from $803.01 to $803.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $804.00 to $804.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.